This study investigated whether common polymorphisms of cytochrome P450 2J2 (CYP2J2), a major enzyme that controls the biosynthesis of vasoactive epoxyeicosatrienoic acids, are collectively involved in the molecular basis of essential hypertension (EH). A total of 2314 unrelated Russian subjects from the Kursk (discovery sample: 913 EH patients and 645 controls) and Belgorod (replication sample: 345 EH patients and 411 controls) regions were recruited for this study. Eight single nucleotide polymorphisms (SNPs), including rs890293, rs11572182, rs10493270, rs1155002, rs2280275, rs7515289, rs11572325, and rs10889162, of CYP2J2 were genotyped using the MassARRAY 4 system and TaqMan-based assays. Significant associations were identified among the SNPs rs890293 (OR = 2.17, 95%CI 1.30–3.65), rs2280275 (OR = 1.59, 95%CI 1.10–2.37) and rs11572325 (OR = 1.89, 95%CI 1.22–2.95) and the risk of EH in females from the Kursk population. Sixteen CYP2J2 genotype combinations only showed significant associations with EH risk only in females. A common haplotype, T-T-G-C-C-C-T-A, increased the risk of EH in females. The bioinformatic analysis enabled identification of the SNPs that possess regulatory potential and/or are located within the binding sites for multiple transcription factors that play roles in the pathways involved in hypertension pathogenesis. Moreover, the polymorphisms rs890293, rs2280275, and rs11572325 were found to be significantly associated with hypertension risk in the Belgorod population. In conclusion, the rs2280275 and rs11572325 SNPs of CYP2J2 may be considered novel genetic markers of hypertension, at least in Russian women. However, sex-specific associations between CYP2J2 gene polymorphisms and hypertension require further investigation to clarify the specific genetic and/or environmental factors that are responsible for the increased disease susceptibility of women compared to that of men.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–72.
Joffres M, Falaschetti E, Gillespie C, Robitaille C, Loustalot F, Poulter N, et al. Hypertension prevalence, awareness, treatment and control in national surveys from England, the USA and Canada, and correlation with stroke and ischaemic heart disease mortality: a cross-sectional study. BMJ Open. 2013;3:e003423 https://doi.org/10.1136/bmjopen-2013-003423
Franceschini N, Le TH. Genetics of hypertension: discoveries from the bench to human populations. Am J Physiol Ren Physiol. 2014;306:F1–F11.
Waken RJ, de Las Fuentes L, Rao DC. A review of the genetics of hypertension with a focus on gene-environment interactions. Curr Hypertens Rep. 2017;19:23.
Basson J, Simino J, Rao DC. Between candidate genes and whole genomes: time for alternative approaches in blood pressure genetics. Curr Hypertens Rep. 2012;14:46–61.
Ehret GB, Caulfield MJ. Genes for blood pressure: an opportunity to understand hypertension. Eur Heart J. 2013;34:951–61.
Padmanabhan S, Caulfield M, Dominiczak AF. Genetic and molecular aspects of hypertension. Circ Res. 2015;116:937–59.
Liu Z, Qi H, Liu B, Liu K, Wu J, Cao H, et al. Genetic susceptibility to salt-sensitive hypertension in a Han Chinese population: a validation study of candidate genes. Hypertens Res. 2017;40:876–84.
Moreno C, Maier KG, Hoagland KM, Yu M, Roman RJ. Abnormal pressure-natriuresis in hypertension: role of cytochrome P450 metabolites of arachidonic acid. Am J Hypertens. 2001;14:90–97.
Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev. 2002;82:131–85.
Askari AA, Thomson S, Edin ML, Lih FB, Zeldin DC, Bishop-Bailey D. Basal and inducible anti-inflammatory epoxygenase activity in endothelial cells. Biochem Biophys Res Commun. 2014;446:633–7.
McGiff JC. Cytochrome P450 metabolism of arachidonic acid. Annu Rev Pharmacol Toxicol. 1991;31:339–69.
Zeldin DC. Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem. 2001;276:36059–62.
Scarborough PE, Ma J, Qu W, Zeldin DC. P450 subfamily CYP2J and their role in the bioactivation of arachidonic acid in extrahepatic tissues. Drug Metab Rev. 1999;31:205–34.
Capdevila JH, Falck JR, Harris RC. Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. J Lipid Res. 2000;41:163–81.
Hoffmann MM, Bugert P, Seelhorst U, Wellnitz B, Winkelmann BR, Boehm BO, et al. The -50G>T polymorphism in the promoter of the CYP2J2 gene in coronary heart disease: the Ludwigshafen Risk and Cardiovascular Health study. Clin Chem. 2007;53:539–40.
Liu PY, Li YH, Chao TH, Wu HL, Lin LJ, Tsai LM, et al. Synergistic effect of cytochrome P450 epoxygenase CYP2J2*7 polymorphism with smoking on the onset of premature myocardial infarction. Atherosclerosis. 2007;195:199–206.
Börgel J, Bulut D, Hanefeld C, Neubauer H, Mügge A, Epplen JT, et al. The CYP2J2 G-50T polymorphism and myocardial infarction in patients with cardiovascular risk profile. BMC Cardiovasc Disord. 2008;8:41.
Marciante KD, Totah RA, Heckbert SR, Smith NL, Lemaitre RN, Lumley T, et al. Common variation in cytochrome P450 epoxygenase genes and the risk of incident nonfatal myocardial infarction and ischemic stroke. Pharm Genom. 2008;18:535–43.
Fava C, Montagnana M, Almgren P, Hedblad B, Engström G, Berglund G, et al. The common functional polymorphism -50G>T of the CYP2J2 gene is not associated with ischemic coronary and cerebrovascular events in an urban-based sample of Swedes. J Hypertens. 2010;28:294–9.
Jie Z, Hong K, Jianhong T, Biao C, Yongmei Z, Jingchuan L. Haplotype analysis of the CYP2J2 gene associated with myocardial infarction in a Chinese Han population. Cell Biochem Funct. 2010;28:435–9.
Xu Y, Ding H, Peng J, Cui G, Liu L, Cianflone K, et al. Association between polymorphisms of CYP2J2 and EPHX2 genes and risk of coronary artery disease. Pharm Genom. 2011;21:489–94.
Zhu Q, Fu Z, Ma Y, Yang H, Huang D, Xie X, et al. A novel polymorphism of the CYP2J2 gene is associated with coronary artery disease in Uygur population in China. Clin Biochem. 2013;46:1047–54.
Arun Kumar AS, Kumar SS, Umamaheswaran G, Kesavan R, Balachandar J, Adithan C. Association of CYP2C8, CYP2C9 and CYP2J2 gene polymorphisms with myocardial infarction in South Indian population. Pharmacol Rep. 2015;67:97–101.
Li Q, Zhao JH, Ma PJ, Su LL, Tao SB, Ji SB. Association of CYP2J2 gene polymorphisms with ischemic stroke. Int J Clin Exp Med. 2015;8:8163–7.
Donnelly MK, Conley YP, Crago EA, Ren D, Sherwood PR, Balzer JR, et al. Genetic markers in the EET metabolic pathway are associated with outcomes in patients with aneurysmal subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2015;35:267–76.
Wang SY, Xing PF, Zhang CY, Deng BQ. Association of CYP2J2 gene polymorphisms with ischemic stroke and stroke subtypes in Chinese population. Med (Baltim). 2017;96:e6266 https://doi.org/10.1097/MD.0000000000006266
King LM, Gainer JV, David GL, Dai D, Goldstein JA, Brown NJ, et al. Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension. Pharm Genom. 2005;15:7–13.
Dreisbach AW, Japa S, Sigel A, Parenti MB, Hess AE, Srinouanprachanh SL, et al. The Prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension. Am J Hypertens. 2005;18:1276–81.
Wu SN, Zhang Y, Gardner CO, Chen Q, Li Y, Wang GL, et al. Evidence for association of polymorphisms in CYP2J2 and susceptibility to essential hypertension. Ann Hum Genet. 2007;71(Pt 4):519–25.
Polonikov AV, Ivanov VP, Solodilova MA, Khoroshaya IV, Kozhuhov MA, Ivakin VE, et al. A common polymorphism G-50T in cytochrome P450 2J2 gene is associated with increased risk of essential hypertension in a Russian population. Dis Markers. 2008;24:119–26.
Alghasham A, Ali A, Ismail H, Dowaidar M, Settin AA. CYP2J2 -50 G/T and ADRB2 G46A gene polymorphisms in Saudi subjects with hypertension. Genet Test Mol Biomark. 2012;16:1027–31.
Tzveova R, Naydenova G, Yaneva T, Dimitrov G, Vandeva S, Matrozova Y, et al. Gender-Specific Effect of CYP2C8*3 on the Risk of Essential Hypertension in Bulgarian Patients. Biochem Genet. 2015;53:319–33.
Polonikov AV, Vialykh EK, Churnosov MI, Illig T, Freidin MB, Vasil'eva OV, et al. The C718T polymorphism in the 3'-untranslated region of glutathione peroxidase-4 gene is a predictor of cerebral stroke in patients with essential hypertension. Hypertens Res. 2012;35:507–12.
Polonikov AV, Ushachev DV, Ivanov VP, Churnosov MI, Freidin MB, Ataman AV, et al. Altered erythrocyte membrane protein composition mirrors pleiotropic effects of hypertension susceptibility genes and disease pathogenesis. J Hypertens. 2015;33:2265–77.
Bushueva O, Solodilova M, Churnosov M, Ivanov V, Polonikov A. The flavin-containing monooxygenase 3 gene and essential hypertension: the joint effect of polymorphism E158K and cigarette smoking on disease susceptibility. Int J Hypertens. 2014;2014:712169.
Polonikov AV, Bushueva OY, Bulgakova IV, Freidin MB, Churnosov MI, Solodilova MA, et al. A comprehensive contribution of genes for aryl hydrocarbon receptor signaling pathway to hypertension susceptibility. Pharm Genom. 2017;27:57–69.
Polonikov AV, Ivanov VP, Belugin DA, Khoroshaya IV, Kolchanova IO, Solodilova MA, et al. Analysis of common transforming growth factor beta-1 gene polymorphisms in gastric and duodenal ulcer disease: pilot study. J Gastroenterol Hepatol. 2007;22:555–64.
GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013;45:580–5.
Melé M, Ferreira PG, Reverter F, DeLuca DS, Monlong J, Sammeth M, et al. The human transcriptome across tissues and individuals. Science. 2015;348:660–5.
Solé X, Guinó E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics. 2006;22:1928–9.
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B. 1995;57:289–300.
Xu Z, Taylor JA. SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res. 2009;37:600–5.
Guo L, Du Y, Chang S, Zhang K, Wang J. rSNPBase: a database for curated regulatory SNPs. Nucleic Acids Res. 2014;42:1033–9.
King LM, Ma J, Srettabunjong S, Graves J, Bradbury JA, Li L, et al. Cloning of CYP2J2 gene and identification of functional polymorphisms. Mol Pharmacol. 2002;61:840–52.
Spiecker M, Darius H, Hankeln T, Soufi M, Sattler AM, Schaefer JR, et al. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation. 2004;110:2132–6.
Tran H, Maurer F, Nagamine Y. Stabilization of urokinase and urokinase receptor mRNAs by HuR is linked to its cytoplasmic accumulation induced by activated mitogen-activated protein kinase-activated protein kinase 2. Mol Cell Biol. 2003;23:7177–88.
Doller A. Akool el-S, Huwiler A, Müller R, Radeke HH, Pfeilschifter J, Eberhardt W. Posttranslational modification of the AU-rich element binding protein HuR by protein kinase C delta elicits angiotensin II-induced stabilization and nuclear export of cyclooxygenase 2 mRNA. Mol Cell Biol. 2008;28:2608–25.
Imig JD. Epoxyeicosatrienoic acids, hypertension, and kidney injury. Hypertension. 2015;65:476–82.
Harper AR, Nayee S, Topol EJ. Protective alleles and modifier variants in human health and disease. Nat Rev Genet. 2015;16:689–701.
Fava C, Ricci M, Melander O, Minuz P. Hypertension, cardiovascular risk and polymorphisms in genes controlling the cytochrome P450 pathway of arachidonic acid: A sex-specific relation? Prostaglandins Other Lipid Mediat. 2012;98:75–85.
Kong A, Thorleifsson G, Gudbjartsson DF, Masson G, Sigurdsson A, Jonasdottir A, et al. Fine-scale recombination rate differences between sexes, populations and individuals. Nature. 2010;467:1099–103.
Buard J, de Massy B. Playing hide and seek with mammalian meiotic crossover hotspots. Trends Genet. 2007;23:301–9.
Lynn A, Schrump S, Cherry J, Hassold T, Hunt P. Sex, not genotype, determines recombination levels in mice. Am J Hum Genet. 2005;77:670–5.
Chowdhury R, Bois PRJ, Feingold E, Sherman SL, Cheung VG. Genetic Analysis of Variation in Human Meiotic Recombination. PLoS Genet. 2009;5:e1000648.
Kondo T, Hirose M, Kageyama K. Roles of oxidative stress and redox regulation in atherosclerosis. J Atheroscler Thromb. 2009;16:532–8.
Maranon R, Reckelhoff JF. Sex and gender differences in control of blood pressure. Clin Sci (Lond). 2013;125:311–8.
Chaudhary KR, Zordoky BN, Edin ML, Alsaleh N, El-Kadi AO. Differential effects of soluble epoxide hydrolase inhibition and CYP2J2 overexpression on postischemic cardiac function in aged mice. Prostaglandins & other lipid mediators. Prostaglandins Other Lipid Mediat. 2012;123:1–10.
Zhao TT, Wasti B, Xu DY, Shen L, Du JQ, Zhao SP. Soluble epoxide hydrolase and ischemic cardiomyopathy. Int J Cardiol. 2012;155:181–7.
Sevre K, Lefrandt JD, Nordby G, Os I, Mulder M, Gans RO, et al. Autonomic function in hypertensive and normotensive subjects: the importance of gender. Hypertension. 2001;37:1351–6.
Liu CC, Kuo TB, Yang CC. Effects of estrogen on gender-related autonomic differences in humans. Am J Physiol Heart Circ Physiol. 2003;285:H2188–2193.
Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension. 2001;37:1199–208.
Safar ME, Smulyan H. Hypertension in women. Am J Hypertens. 2004;17:82–87.
Shim CY, Park S, Choi D, Yang WI, Cho IJ, Choi EY, et al. Sex differences in central hemodynamics and their relationship to left ventricular diastolic function. J Am Coll Cardiol. 2011;57:1226–33.
Koenig J, Thayer JF. Sex differences in healthy human heart rate variability: a meta-analysis. Neurosci Biobehav Rev. 2016;64:288–310.
Evangelista EA, Kaspera R, Mokadam NA, Jones JP 3rd, Totah RA. Activity, inhibition, and induction of cytochrome P450 2J2 in adult human primary cardiomyocytes. Drug Metab Dispos. 2013;41:2087–94.
Ma J, Graves J, Bradbury JA, Zhao Y, Swope DL, King L, et al. Regulation of mouse renal CYP2J5 expression by sex hormones. Mol Pharmacol. 2004;65:730–43.
Athirakul K, Bradbury JA, Graves JP, DeGraff LM, Ma J, Zhao Y, et al. Increased blood pressure in mice lacking cytochrome P450 2J5. FASEB J. 2008;22:4096–108.
Zhestovskaja AS, Kukes VG, Sychev DA. Personalized medicine: myth or reality? The position of Russian clinical pharmacologists. EPMA J. 2013;4:13.
Chen Q, Wei D. Human cytochrome P450 and personalized medicine. Adv Exp Med Biol. 2015;827:341–51.
The study was supported by the Russian Science Foundation (№15-15-10010).
Conflict of interest
The authors declare that they have no conflict of interest.
Electronic supplementary material
About this article
Cite this article
Polonikov, A.V., Ponomarenko, I.V., Bykanova, M.A. et al. A comprehensive study revealed SNP–SNP interactions and a sex-dependent relationship between polymorphisms of the CYP2J2 gene and hypertension risk. Hypertens Res 42, 257–272 (2019). https://doi.org/10.1038/s41440-018-0142-1